Published Online: Saturday, July 1, 2006

Community Care Rx (CCRx) recently launched its Welcome to CCRx Medication Review Program, a program created to help new members and improve their transition into CCRx's Medicare Part D plan. The outcome elevates the quality of care to beneficiaries through face-to-face meetings with their community pharmacists for a timely review of their drug regimens as they enroll in the prescription drug benefit. The Medication Review Program will be a reimbursable service for pharmacists.

CCRx officials are aware that one-on-one encounters with the patient's pharmacists can be more effective to guarantee clinically appropriate and timely medication transitions. During a Medication Review, community pharmacists will work with CCRx beneficiaries to evaluate their current medication use and make suggestions related to the following:

  • Clinical concerns, including potentially harmful drug interactions
  • Transition planning for drugs that are not part of the CCRx formulary
  • Ways to reduce beneficiaries'costs by switching to less expensive or preferred brand drugs

"We believe that CCRx is taking a gigantic step in the right direction by engaging the services of the community pharmacist to better care for Medicare beneficiaries," said Bruce Roberts, RPh, executive vice president and chief executive officer for the National Community Pharmacists Association. "Community pharmacists are medication experts, and their patients have a high comfort level and trust in them."

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues